Streetbeat News

Price Targets

LPLA

Barclays analyst Jeremy Campbell maintains an Overweight rating on LPL Financial Holdings (LPLA) and raises the price target from $275 to $277.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 2:03 pm

JRVR

Barclays analyst Tracy Benguigui has maintained an Equal-Weight rating on James River Gr Hldgs (NASDAQ:JRVR) but lowered the price target from $17 to $15.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 2:01 pm

ICE

Barclays analyst Jeremy Campbell has maintained an Equal-Weight rating on Intercontinental Exchange (NYSE:ICE) and lowered the price target from $122 to $120.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 2:00 pm

IBKR

Barclays analyst Benjamin Budish maintains an Overweight rating on Interactive Brokers Gr (NASDAQ:IBKR) and raises the price target from $106 to $110.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 1:58 pm

FE

Barclays analyst Eric Beaumont has maintained an Equal-Weight rating on FirstEnergy (NYSE:FE) and lowered the price target from $37 to $35.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 1:56 pm

EQH

Barclays analyst Theresa Chen maintains an Overweight rating on Equitable Hldgs (NYSE:EQH) but lowers the price target from $33 to $32.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 1:53 pm

SNDR

Benchmark analyst Christopher Kuhn has reiterated a 'Buy' rating on Schneider National (NYSE:SNDR) and maintained a price target of $34.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 1:52 pm

EA

Benchmark analyst Mike Hickey has reiterated a 'Buy' rating on Electronic Arts (NASDAQ:EA) and maintained a price target of $153.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 1:47 pm

BABA

Benchmark analyst Fawne Jiang has reiterated a 'Buy' rating on Alibaba Gr Holding (NYSE:BABA) and maintained a price target of $180.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 1:45 pm

ALNY

BMO Capital analyst Kostas Biliouris has maintained an 'Outperform' rating on Alnylam Pharmaceuticals (NASDAQ:ALNY), but lowered the price target from $250 to $234.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 1:42 pm